A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Inclusion Criteria:

• Have histologically confirmed, unresectable locally advanced or metastaticurothelial cancer (mUC). Individuals with mixed histology other than small cell orneuroendocrine carcinoma are eligible if a urothelial component is present.

• Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alterationdetermined via molecular testing from a tumor or blood sample obtained at or anytime after diagnosis of advanced or metastatic urothelial cancer.

• Have measurable disease by investigator assessment defined by Response EvaluationCriteria in Solid Tumors (RECIST) v1.1

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Have adequate laboratory parameters

Exclusion Criteria:

• Have received prior systemic therapy for locally advanced or metastatic urothelialcancer (mUC).

• Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria forAdverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemictherapy.

• Have ongoing sensory or motor neuropathy of Grade 2 or higher

• Have untreated or uncontrolled central nervous system (CNS) involvement or anyhistory of leptomeningeal disease.

• Current evidence corneal keratopathy or retinal disorder confirmed by ocularexamination at screening.